Xie Xuewei, Zhong Chongke, Liu Xin, Pan Yuesong, Wang Aili, Wei Yufei, Liu Dacheng, Xu Tan, Jiang Yong, Wang Mengxing, Jing Jing, Meng Xia, Obst Katherine, Chen Chung-Shiuan, Wang David, Wang Yilong, Zhang Yonghong, He Jiang, Wang Yongjun, Liu Liping
Department of Neurology (X.X., X.L., Y.P., Yufei Wei, Y.J., M.W., J.J., X.M., Yilong Wang, Yongjun Wang, L.L.), Beijing Tiantan Hospital, Capital Medical University, China.
China National Clinical Research Center for Neurological Diseases, Beijing, China (X.X., X.L., Y.P., Yufei Wei, Y.J., M.W., J.J., X.M., Yilong Wang, Yongjun Wang, L.L.).
Stroke. 2025 Mar;56(3):631-639. doi: 10.1161/STROKEAHA.124.049242. Epub 2025 Jan 14.
We performed a prespecified subgroup analysis of the CATIS-2 trial (China Antihypertensive Trial in Acute Ischemic Stroke II) to compare the effect of early versus delayed antihypertensive treatment on death and disability in patients with and without medical history of hypertension.
CATIS-2 is a multicenter randomized clinical trial conducted in 106 hospitals in China. The trial randomized 4810 patients with acute ischemic stroke within 24 to 48 hours of symptom onset and elevated systolic blood pressure between 140 and <220 mm Hg to receive antihypertensive treatment immediately after randomization or to discontinue antihypertensive medications for 7 days and then receive treatment on day 8. The primary outcome was a combination of death or functional dependency (modified Rankin Scale score ≥3) at 90 days.
At the 90-day follow-up, the primary outcome of death or functional dependency was not different between early- and delayed-treatment groups according to the history of hypertension; the odds ratios (95% CIs) associated with the early-treatment group were 1.11 (0.91-1.36) and 1.38 (0.92-2.08) for participants with and without a history of hypertension. However, the ordinal logistic regression showed that early antihypertensive treatment was associated with the odds of a higher modified Rankin Scale score in patients without hypertension (odds ratio, 1.35 [95% CI, 1.01-1.82]), but not in those with hypertension (odds ratio, 0.95 [95% CI, 0.82-1.10]; =0.04 for interaction).
Early antihypertensive treatment did not reduce the odds of dependency or death at 90 days by hypertension history among patients with ischemic stroke but worsened functional outcomes for patients without hypertension in the ordinal analysis.
URL: https://www.clinicaltrials.gov; Unique identifier: NCT03479554.
我们对CATIS-2试验(中国急性缺血性卒中降压治疗试验II)进行了一项预先设定的亚组分析,以比较早期与延迟降压治疗对有或无高血压病史患者的死亡和残疾影响。
CATIS-2是一项在中国106家医院进行的多中心随机临床试验。该试验将4810例症状发作后24至48小时内且收缩压升高至140至<220 mmHg的急性缺血性卒中患者随机分为两组,一组在随机分组后立即接受降压治疗,另一组停用降压药物7天,然后在第8天接受治疗。主要结局是90天时死亡或功能依赖(改良Rankin量表评分≥3)的综合情况。
在90天随访时,根据高血压病史,早期治疗组和延迟治疗组在死亡或功能依赖的主要结局方面没有差异;有高血压病史和无高血压病史参与者的早期治疗组的比值比(95%可信区间)分别为1.11(0.91-1.36)和1.38(0.92-2.08)。然而,有序逻辑回归显示,早期降压治疗与无高血压患者较高的改良Rankin量表评分的比值相关(比值比,1.35 [95%可信区间,1.01-1.82]),但与有高血压患者无关(比值比,0.95 [95%可信区间,0.82-1.10];交互作用P = 0.04)。
早期降压治疗在90天时并未根据缺血性卒中患者的高血压病史降低依赖或死亡的几率,但在有序分析中,无高血压患者的功能结局恶化。